Related Experiment Video
Updated: May 5, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
A TRIM Family-Based Strategy for TRIMCIV Target Prediction in a Pan-Cancer Context with Multi-Omics Data and Protein
Yisha Huang1, Jiajia Xuan1, Jiayan Liang1
1MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
None:
The TRIM CIV subfamily, distinguished by its C-terminal PRY-SPRY domains, constitutes nearly half of the human TRIM family and plays pivotal roles in cancer progression through ubiquitination. Identifying TRIM CIV substrates and interactors has emerged as a critical approach for elucidating tumorigenesis. Current protein-protein interaction (PPI) prediction models face challenges, including an inherent deficiency of negative datasets, biased feature integration, and the absence of a cancer-specific interaction context. To achieve the precise identification of TRIMCIV targets, we developed TRIMCIVtargeter with predictive models that systematically integrates multi-dimensional PPI features-expression differences and correlations in specific cancer, comparable protein-docking scores, and cancer-specific context. Learning from the functional and structural interaction features between 718 experimentally validated TRIM-target pairs, two types of SVM-based binary models were independently trained using proteomic and transcriptomic data. Our models achieved robust prediction performance in cancers utilizing a fair feature space and circumventing hypothetical non-interacting pairs. TRIMCIVtargeter not only provides a cancer-related resource for studying TRIMCIV-mediated regulatory mechanisms but also offers a new perspective for family-specific PPI prediction, holding significant implications for biomarker discovery and therapeutic targeting in oncology. The online platform of TRIMCIVtargeter is now available.

